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Introduction: Protective host responses in those exposed to or infected with
tuberculosis (TB) is thought to require a delicate balance between pro-inflammatory
and regulatory immune responses. Myeloid-derived suppressor cells (MDSCs), regulatory
cells that dampen T-cell function, have been described in cancer and other infectious
diseases but there are limited data on their role in TB.
Methods: Peripheral blood was obtained from patients with active pulmonary TB and
participants with presumed latent TB infection (LTBI) from Cape Town, South Africa.
MDSC frequency was ascertained by flow cytometry. Purified MDSCs were used to
assess (i) their suppressive effect on T-cell proliferation using a Ki67 flow cytometric assay
and (ii) their effect on mycobacterial containment by co-culturing with H37Rv-infected
monocyte-derived macrophages and autologous pre-primed effector T-cells with or
without MDSCs. Mycobacterial containment was measured by plating colony forming
units (CFU).
Results: MDSCs (CD15+HLA-DR-CD33+) had significantly higher median frequencies
(IQR) in patients with active TB (n=10) versus LTBI (n= 10) [8.2% (6.8-10.7) versus 42.2%
(27–56) respectively; p=0.001]. Compared to MDSC-depleted peripheral blood
mononuclear and effector T cell populations, dilutions of purified MDSCs isolated from
active TB patients suppressed T-cell proliferation by up to 72% (n=6; p=0.03) and
significantly subverted effector T-cell-mediated containment of H37Rv in monocyte-
derived macrophages (n=7; 0.6% versus 8.5%; p=0.02).
Conclusion: Collectively, these data suggest that circulating MDSCs are induced during
active TB disease and can functionally suppress T-cell proliferation and subvert
mycobacterial containment. These data may inform the design of vaccines andorg June 2021 | Volume 12 | Article 6766791
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Frontiers in Immunology | www.frontiersin.immunotherapeutic interventions against TB but further studies are required to
understand the mechanisms underpinning the effects of MDSCs.Keywords: myeloid derived suppressor cells, MDSC, tuberculosis, immunology, biomarkersINTRODUCTION
Tuberculosis (TB) is the leading cause of death due to a single
infectious agent (1). Although TB is largely a curable disease with
a global treatment success rate of ~85%, almost 1.5 million
people succumbed to the disease in 2019 (1). This is likely to
worsen due the rapid emergence and global spread of drug
resistant forms of the disease which threaten to derail advances
in TB control (2). Eradication of TB is only likely to be achieved
with an effective vaccine. Currently, the only licensed TB vaccine
is an attenuated strain of Mycobacterium bovis (M.bv), BCG (3).
BCG confers protection against severe forms of TB disease in
children but offers limited protection (~30%) against adult forms
of pulmonary disease (4). Data from recently trialled vaccine
candidates have not offered much hope. For instance, MVA85A
did not show any improvement compared to BCG despite
compelling pre-clinical animal data (5), and the more recently
trailed M72/AS01 performed much better but was still only
associated with an efficacy of only ~50% (6). These studies and
their outcomes highlight our incomplete understanding of the
immune mechanisms underpinning protective immunity and
bacterial persistence.
One of the central hallmarks of active TB disease is a failed T-
cell effector immune response (7). However, there is still much
that is not known about the specific immune mechanisms
underpinning failed T-cell immunity (8). In active TB disease
immunity associated with recovery is traditionally thought to be
primarily driven by pro-inflammatory effector T-cells, and
cytotoxic CD8 cells (8). However, the host immunity also
involves several regulatory mechanisms for suppressing T-cell
responses against M. tb-specific antigens, which may be
leveraged by pathogens to their advantage. Such strategies may
also underpin the extensive immunopathology associated
with TB.
Myeloid-derived suppressor cells (MDSCs) is one type of
regulatory cell that potently regulates cancer immunity at the site
of pathology (9). MDSCs have a morphology similar to
granulocytes and/or monocytes (10). In healthy individuals,
immature myeloid cells are generated in the bone marrow and
rapidly differentiate into mature macrophages, dendritic cells,
or granulocytes (10). MDSCs can broadly be classified
into three groups: 1) early-stage-MDSC (LIN1-HLA-DR-/low
CD11B+CD33+), 2) polymorphonuclear-MDSC (HLA-DR-/low
CD14-CD15+CD33+/dim), and 3) monocytic-MDSC (HLA-
DR-/lowCD14+CD15-CD33+) (10). This report specifically
focuses on polymorphonuclear-MDSCs (PMN-MDSCs), also
known as granulocytic-MDSCs.
Others have previously shown that regulatory pathways (11,
12), including MDSCs are upregulated in patients with active TB
(13–17), their frequency in peripheral blood decreases withorg 2successful treatment (14), and MDSCs are able to inhibit T-cell
proliferation (13). However, data are limited to a handful of
studies (less than 5), and there are hardly any data from humans
or TB-endemic settings (13). Furthermore, there are no
published data about the biological significance of these cells
and the ability of MDSCs to directly restrict mycobacterial
growth. Thus, their role during M. tb infection remains
unclear. To address these knowledge gaps, we explored the
levels of M-MDSCs in patients with active TB versus those
who are latently infected, and whether they abrogated the
ability of effector T-cells to contain mycobacterial growth.METHODS
Participants and Ethical Approval
HIV-uninfected participants were recruited from various
primary healthcare clinics around Cape Town between January
2017 and February 2019. Presumed LTBI participants were
healthy asymptomatic individuals with no clinical or
radiological evidence of previous or active TB disease and were
both tuberculin skin test (TST; induration >10mm) and
interferon-gamma release assay (QuantiFERON®-TB Gold)
positive. TB patients were microbiologically confirmed by
sputum smear microscopy, Xpert MTB/RIF, and/or MGIT
sputum culture, and had <1 week of anti-TB therapy at the
time of recruitment. Informed written consent was obtained
from all patients and the study was approved by the UCT
Research Ethics Committee. Participants were excluded from
the study if they were HIV-infected, pregnant or younger than 18
years of age.
Flow Cytometry
Peripheral blood was obtained from all study participants by
venipuncture. 100ml whole blood were seeded in a 96-well tissue
culture plate and either left unstimulated or stimulated with
12mg/ml purified protein derivative (PPD; Statens Serum
Institute) overnight at 37°C with 5% CO2. The cells were
subsequently stained using fluorescently labelled antibodies
specific for cell surface markers [CD14, CD33, HLA-DR and
CD15; (BD Biosciences, Ebiosciences, Biolegend)]. Thereafter,
the cells were fixed in 4% paraformaldehyde and data acquired
on an LSRII flow cytometer.
Myeloid-Derived Suppressor
Cells Isolation
MDSCs were isolated as previously described by Lechner et al.
(18), with modifications. Briefly, whole blood was separated over a
density gradient (Histopaque 1077, Sigma-Aldrich) into theJune 2021 | Volume 12 | Article 676679
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granulocyte layer. The layer containing erythrocytes and
granulocytes were harvested and erythrocytes were lysed (BD
cell lysis solution). The granulocytic cell fraction was incubated
with CD15 MACSiBead particles for positive selection of CD15
cells. HLA-DR- cells were isolated from the CD15+ cell fraction by
immuno-magnetic separation (MACS beads, MACS LS-column,
Miltenyi Biotec). The CD15+HLA-DR- cell fraction was incubated
with CD33 microbeads for positive selection of CD15+HLA-DR-
CD33+ cells (Miltenyi Biotec). Purity of the MDSC population
exceeded 95% as confirmed by flow cytometry.
Ki67 Suppression Assay
The suppressive effect of MDSCs on T-cell proliferation was
evaluated using a Ki67 flow cytometry proliferation assay, as
previously described (11). Briefly, on day 0, PBMCs were co-
cultured with purified MDSCs as follows: duplicate wells
containing 0.5x106 PBMCs were stimulated with PPD (12mg/
ml) to generate effector T-cells and co-cultured with MDSCs at
ratios of 1:1, 2:1 and 4:1 (PBMCs: MDSCs) for 6 days at 37°C and
5% CO2. Additional experimental control wells were set up
including (1) unstimulated PBMCs as a negative control; and
(2) PBMCs stimulated with PPD (12mg/ml) as a proliferation
control. On day 6, the cells were harvested and stained for Ki67
expression as per manufacturer instructions (Biolegend, USA).
Briefly, the cells were harvested and washed with cold 70%
ethanol and, after centrifugation, stained for Ki67, CD3, CD33,
CD15 and HLA-DR (Biolegend, USA). Data was acquired on an
LSR-II flow cytometer and analysed using FACSDiva software.
The percentage (%) proliferation was calculated as follows:
[(% MDSC+Ki67+ cells in experimental condition/% MDSC+Ki67+
cells in proliferation control) X 100]. The percentage suppression
was calculated as 100 – (% proliferation).
Mycobacterial Containment Assay
A mycobacterial containment assay was used, as previously
described (11), to determine the effect of MDSCs on the ability
of PPD-driven effector T-cells to effectively contain M. tb within
blood monocyte-derived macrophages (MDMs). 1x106/ml
PBMCs were seeded into a tissue culture plate and were
cultured undisturbed for 5 days to allow monocytes to adhere
to the plastic and differentiate into macrophages. Thereafter, the
plate was washed to remove non-adherent cells and the MDMs
were infected with H37Rv at a multiplicity of infection (MOI) of
1:1. In parallel, purified MDSCs were co-cultured with PPD-
stimulated PBMCs (12mg/ml) at specific ratios [MSDC: Teff at 1:2
(5x104:10X104 cells); and 1:4 (2.5x104:10X104 cells)] and
incubated for 6 days at 37°C and 5% CO2. The various effector
T-cell/MDSC combinations were subsequently co-cultured with
H37Rv-infected macrophages for 24 hours. Additional wells
included a reference control containing H37Rv-infected MDMs
only, a positive M. tb containment control containing H37Rv-
infected MDMs co-cultured with effector T-cells (Teff).
Intracellular M.tb, released by lysis of infected MDMs, was
subsequently cultured on Middlebrook 7H10 agar and
expressed as colony forming units per ml (CFU/ml). The
percentage (%) mycobacterial containment was also reportedFrontiers in Immunology | www.frontiersin.org 3and was defined as the reduction in M. tb survival compared to
the reference control (H37Rv infected MDM only).
Statistical Analysis
The data were tested for normality using the Shapiro-Wilk test.
The Mann Whitney t test was used to assess immuno-
phenotyping differences between the participant’s groups. The
Wilcoxon ranked sum test was used to assess differences within
participant groups. Statistical analyses were performed using
GraphPad Prism version 6.0 (GraphPad software) and SPSS
Statistics version 23 (SPSS Inc.).RESULTS
Clinical Characteristics of
Study Participants
A total of 33 HIV-uninfected participants were recruited and
classified into 2 groups (Table 1): microbiologically-confirmed
participants with pulmonary TB (TB; n=23), and presumed-
latently infected participants (LTBI; n=10) as determined by a
positive tuberculin skin test (TST-positive) and Quantiferon
Gold in-tube test (both positive). All participant groups were
matched for age, sex and gender (Table 1); univariate analysis
showed that good matching was achieved. All participants had
no previous history of TB.
Frequency of Myeloid-Derived Suppressor
Cells in Peripheral Blood
In peripheral blood stimulated with PPD, we found a significant
increase in the frequency of MDSCs (HLA-DR-/lowCD14+CD15-
CD33+) in patients with active TB (median = 42.2%; IQR: 28.1–
56.3) compared to participants with LTBI (median = 8.2%; IQR:
7.6 – 10.2; p < 0.001; Figure 1).TABLE 1 | Demographics and clinical characteristics of participants with latent







Patient numbers (n) 10 23 33 NA
Age (years; aIQR) 32 (28-49) 35 (26-48) 34 (26-49) 0.34
Gender (%)
Male 5 (50) 12 (52) 17 (52) 0.89
Female 5 (50) 11 (48) 16 (48)
Ethnicity (%)
Black African 3 (30) 9 (39) 12 (36) 0.74
Mixed race 4 (40) 10 (44) 14 (42)
European descent 3 (30) 4 (17) 7 (21)
Median duration of
treatment
prior to blood donation
(days; aIQR)
NA 5 (4-12) 5 (4-12) NA
Smear status
Smear 1+ positive (%) NA 3 (13) NA NA
Smear 2+ positive (%) NA 12 (52) NA
Smear 3+ positive (%) NA 8 (35) NAJune 2021 | Volume 12 | Article 6NA, not applicable.76679
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The functional capability of the MDSC to suppress PPD-driven
effector T-cell proliferative responses was evaluated using a Ki67
flow cytometry assay. MDSCs were isolated from the peripheral
blood of patients with active TB disease (n=6). MDSC purity was
confirmed to be greater than 95% (Table 1, online supplement).
The proliferation control, which contained PPD-driven effector
T-cells only, displayed limited T-cell suppression (median
10.95%; range: 6.75 – 19.25% T-cell suppression; Figure 2B).
However, the addition of MDSCs to PPD-driven effector T-cells
at ratios of 1:1, 2:1, and 4:1 (effector T cells: MDSCs) resulted in
significant suppression of T-cells [median (range): 75% (72.62 –
95.9%), 69% (61.25 – 89.70%) and 65% (59.05 – 84%) T-cell
suppression respectively; Figure 2].
Mycobacterial Containment Assay
The mycobacterial containment assay was used to determine the
effect of MDSC, isolated from the peripheral blood of patients
with active TB (n= 7), on the ability of PPD-driven effector T-
cells to effectively contain M. tb within autologous MDMs.
In terms of absolute CFUs, a significant decrease was observed in
wells containing effector T-cells (Teff) co-cultured with H37Rv-
infected MDMs (Teff; 4.3X10
4 CFU/ml) compared to wells onlyFrontiers in Immunology | www.frontiersin.org 4containing H37Rv infected MDMs (MDM only; 7.1X104 CFU/ml;
p=0.0002; Figure 2C). However, when MDSCs and effector T-cells
were co-cultured with H37Rv-infected MDMs, there was an
increase in CFU/ml compared to the Teff well (p=0.02; Figure 2C).
The same data, for greater clarity, were also differently
expressed as % mycobacterial (M.tb) containment, defined as the
% change in CFU/ml relative to the H37Rv-infected MDMs
reference control. As such, the H37Rv-infected MDM control or
reference represented 0% M. tb containment, or in other words,
100% M.tb survival. The addition of effector T-cells together with
the H37Rv-infected MDMs, represented the “positive control”. In
the positive control 30.6% M.tb containment was observed,
however this level of containment was significantly reduced
when MDSCs were introduced into the culture (2:1 = 9.2% and
4:1 = 8.5% M.tb containment; p=0.02).DISCUSSION
We found that patients with active TB disease had significantly
higher frequencies of circulating MDSCs. These cells suppressed
the proliferative capabilities of PPD-specific effector T cells and
attenuated mycobacterial containment in vitro.
The role of MDSCs in TB has been contentious. We have
shown, for the first time in humans, that MDSCs canmodulate T-
cell activity, thus enhancing mycobacterial growth in vitro. Our
results indicate that MDSCs can modulate an immune response
that favours M.tb survival. The mechanism by which this occurs
deserves further study. Previous murine studies that examined the
direct effect of MDSCs on mycobacterial survival, showed that
infected MDSCs were unable to directly kill mycobacteria (19),
despite their ability to produce nitric oxide (20). Knaul et al.
found that M.tb-infected MDSCs, similar to macrophages, can
release pro-inflammatory (IL-1 and IL-6), but also anti-
inflammatory cytokines (IL-10), thus providing a possible
mechanism for our observations (21). However, further work in
now required to study an array of possible mechanisms by which
might potentially including Th2 cytokines, cell-to-cell contact,
and other humoral mechanisms etc.
We found the levels of MDSC were significantly higher in
patients with active TB compared to those with presumed-LTBI,
and that MDSCs suppressed T-cell proliferation. Indeed, MDSCs
were first described as suppressor cells recruited to tumor sites
(10), where the increased levels of MDSCs significantly
correlated with aggressive disease, poor patient prognosis and
immune escape (18). More recently, MDSCs were shown to be
upregulated during active TB disease in adults (13, 14) and in
HIV-TB co-infected children (17), and in the same patients are
able to suppress T cell proliferation (13, 14) and alter cytokine
expression (13). However, although we confirm these
observations, we have extended these findings to show that the
anti-proliferative and immune-modulatory effects translate into
sub-optimal mycobacterial containment.
There are several limitations to our findings. The immuno-
phenotype of study participants was analysed in the peripheral
blood compartment, and whether these effects occur at the site ofA
B
FIGURE 1 | Frequency of myeloid derived suppressor cells (MDSC) in the
peripheral blood compartment of participants with presumed-latent infection
and active TB. (A) Flow cytometry gating strategy. Cells were first gated on
CD14-CD33+ cells, and within this population HLA DRlow/-CD15+ cells were
identified. (B) frequency of CD14-CD33+HLA-DRlow/-CD15+ MDSCs before
and after stimulation with PPD and PHA. p-value of <0.05 were considered
significant (Mann-Whitney unpaired t-test). ***p-value <0.0001.June 2021 | Volume 12 | Article 676679
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is constrained by cost, ethical and infection control considerations.
Second, our study sample size was limited, and we only recruited
patients from one geographical setting. Nevertheless, we were able
to demonstrate statistically significant differences between the
groups, which together with the impact on proliferation, suggest
that these are likely biologically meaningful observations. Third,
we did not explore the immune mechanism by which MDSCs
subverted the ability of T-cells to kill M.tb. However, this was
limited by available funding but is likely to begin shortly.
Fourth, containment was used to define how MDSCs can
modulate the function of effector T cells to control M. tb. As
described in our previous publication (22), it is difficult to
quantify anti-mycobacterial activity as our assay cannot
distinguish between organisms that have been killed or those
that have entered a non-replicating state. However, containment
is a much more biologically meaningful outcome measure as
compared to biomarker proxies, including cytokines or receptorFrontiers in Immunology | www.frontiersin.org 5signaling pathways, that may indicate protection. Although the
latter are commonly used in human studies, they may merely
represent a bystander effect rather than having a causal link.
In conclusion, persons with active TB disease, compared to those
with presumed-LTBI, demonstrate an altered immuno-phenotype
characterized by a high frequency of MDSCs. MDSCs isolated from
patients with active TB disease were highly suppressive and could
attenuate mycobacterial containment in vitro. Collectively, these
data suggest a contributing role for MDSCs in the immuno-
pathogenesis of TB and MDSCs may be potential targets that
could be exploited to design vaccines or host-directed therapies.AUTHOR’S NOTE
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